New therapeutic agents for acromegaly.
Los Angeles, United States. In Nat Rev Endocrinol, Feb 2016
The currently available somatostatin receptor ligands (SRLs) and growth hormone (GH) antagonists are used to control levels of GH and insulin-like growth factor 1 (IGF-1) in patients with acromegaly.
Current therapies and mortality in acromegaly.
Bucureşti, Romania. In J Med Life, Oct 2015
A meta-analysis proved that mortality is much lower in operated patients, even uncured, than the entire group of patients and is similar with the general population in patients with GH<1 μg/ L. For the patients with hypersecreting postoperative remnant tumor, those with low chance of surgical cure or with life-threatening comorbidities, medical therapies are available: somatostatin receptor analogues (SRA), dopamine agonists (DA) and GH receptor antagonists.
Pathology: Classification and Immunoprofile.
Bern, Switzerland. In Front Horm Res, 2014
There is no predictive biomarker in use, with the exception of somatostatin receptor (SSTR) 2 expression for predicting the amenability of a tumor to in vivo SSTR targeting for imaging or therapy.
Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
India. In N Engl J Med, 2014
METHODS: We conducted a randomized, double-blind, placebo-controlled, multinational study of the somatostatin analogue lanreotide in patients with advanced, well-differentiated or moderately differentiated, nonfunctioning, somatostatin receptor-positive neuroendocrine tumors of grade 1 or 2 (a tumor proliferation index [on staining for the Ki-67 antigen] of <10%) and documented disease-progression status.
Resistance to somatostatin analogs in acromegaly.
Napoli, Italy. In Endocr Rev, 2011
Predictors of response are patients' gender, age, initial GH and IGF-I levels, and tumor mass, as well as adequate expression of somatostatin receptor types 2 and 5, those with the highest affinity for octreotide and lanreotide.